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ARTICLE
Persistence of adoptively transferred T cells with
a kinetically engineered IL-2 receptor agonist
Giulia Parisi1, Justin D. Saco1, Felix B. Salazar2, Jennifer Tsoi1, Paige Krystofinski1, Cristina Puig-Saus1,
Ruixue Zhang1, Jing Zhou3, Gardenia C. Cheung-Lau4, Alejandro J. Garcia1, Catherine S. Grasso1,5,
Richard Tavaré6, Siwen Hu-Lieskovan1, Sean Mackay3, Jonathan Zalevsky7, Chantale Bernatchez8, Adi Diab8,
Anna M. Wu 2,9, Begoña Comin-Anduix4,5,10, Deborah Charych7,11 & Antoni Ribas 1,4,5,10*
Interleukin-2 (IL-2) is a component of most protocols of adoptive cell transfer (ACT) therapy
for cancer, but is limited by short exposure and high toxicities. NKTR-214 is a kinetically-
engineered IL-2 receptor βγ (IL-2Rβγ)-biased agonist consisting of IL-2 conjugated to multiple
releasable polyethylene glycol chains resulting in sustained signaling through IL-2Rβγ. We
report that ACT supported by NKTR-214 increases the proliferation, homing and persistence
of anti-tumor T cells compared to ACT with IL-2, resulting in superior antitumor activity
in a B16-F10 murine melanoma model. The use of NKTR-214 increases the number of
polyfunctional T cells in murine spleens and tumors compared to IL-2, and enhances the
polyfunctionality of T and NK cells in the peripheral blood of patients receiving NKTR-214 in a
phase 1 trial. In conclusion, NKTR-214 may have the potential to improve the antitumor
activity of ACT in humans through increased in vivo expansion and polyfunctionality of the
adoptively transferred T cells.
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Adoptive cell transfer (ACT) of T cells that recognize spe-cific tumor antigens has achieved promising results inpatients with advanced cancers1. Clinical protocols of
ACT infusing ex vivo expanded tumor-infiltrating lymphocytes
(TIL) or T cell receptor (TCR) engineered peripheral blood T cells
require the concomitant administration of interleukin 2 (IL-2,
aldesleukin), usually administered intravenously at the highest
tolerated dose every 8 h in an inpatient hospital setting to support
expansion and function of the adoptively transferred cells2. This
dosing regimen results in a high peak of exposure explaining the
acute toxicities, which is of very short duration and suboptimally
activates the IL-2 receptor3. There have been attempts at
decreasing the toxicity and improving the pharmacokinetics of
IL-2 by lowering the doses and administering subcutaneously, but
it is unclear if the benefit is maintained compared to high dose IL-
24. In addition, IL-2 has pleiotropic stimulatory effects by acti-
vating effector T cells and natural killers (NK) through the
binding of the intermediate-affinity heterodimeric receptor IL-
2Rβγ, but it also interacts with the high affinity heterotrimeric
receptor complex IL-2Rαβγ promoting expansion of regulatory
T cells (Tregs), which have known immune suppressive roles in
the tumor microenvironment5–7. These limitations imposed by
high dose IL-2 have restricted the use of ACT in the clinic8.
Different strategies have been pursued in order to develop
gamma chain-signaling cytokines with an improved safety profile
relative to the native IL-2 cytokine and that selectively expand
effector T cells over Tregs9–12. NKTR-214 (also known as bem-
pegaldesleukin) is a prodrug with the same amino acid sequence
as the clinically approved IL-2, but which is conjugated with
multiple releasable chains of polyethylene glycol (PEG). In its
prodrug form, NKTR-214 does not bind to IL-2 receptors and
does not activate T cell signaling. However, when exposed to
physiological conditions, the PEG chains sequentially release over
time, allowing the cytokine to bind and trigger signaling through
the IL-2 receptor complex. In its most active forms, 1-PEG-IL-2
and 2-PEG-IL-2, the position of the PEGylation reduces the
interaction between IL-2 and its cognate IL-2Rα subunit, while
the affinity to the IL-2Rβγ complex remains relatively
unchanged3,13. Prior studies have provided evidence that the
preferential activation of IL-2Rβγ over IL-2Rα results in an
increased ratio of tumor-killing CD8 T cells to Treg in NKTR-214
treated mice compared with IL-2 (400 versus 18 fold, respec-
tively)3,13. Free unconjugated-IL-2 is essentially undetectable as it
clears faster than it forms. NKTR-214 as a monotherapy and in
combination with anti-PD-1 antibodies or Toll-like receptors
(TLR) agonists, is currently being evaluated in an outpatient
setting in several clinical trials, showing early evidence of efficacy
in multiple tumor types along with a favorable outpatient
dosing14.
In the current work, we test the hypothesis that co-
administered NKTR-214 can outperform IL-2 to improve the
in vivo expansion, activation, and persistence of adoptively
transferred effector T cells to improve anti-tumor efficacy. To
test this principle, we used the pre-clinical pmel-1 mouse model
to study the behavior of tumor-specific CD8 T cell expansion
when NKTR-214 is combined with ACT compared to ACT+
IL-2. All CD8 T cells from pmel-1 mice have a transgenic T cell
receptor (TCR) specific for the melanoma antigen gp100
expressed by B16-F10 murine melanoma cells. This model
allows controlled evaluation of the anti-tumor activity, biodis-
tribution, in vivo functionality, and gene expression profile
from these T cells when combined with either NKTR-214 or
IL-2. In addition, we analyze the T cell polyfunctionality of
murine T cells and also explore the polyfunctionality of human
T cells obtained from patients treated with NKTR-214 within a
single agent, phase I clinical trial.
Results
ACT+NKTR-214 achieves long-lasting anti-tumor responses.
The anti-tumor effects of NKTR-214 to support the expansion
and functionality of adoptively transferred antitumor T cells was
evaluated in mice bearing established B16-F10 murine melanoma
tumors larger than 150mm3 at the time of ACT. C57BL/6 mice
were implanted with B16-F10 and received pmel-1 Thy1.1+ T
lymphocytes activated in vitro with gp100 peptide followed by
systemic treatment with either IL-2 or NKTR-214 after a lym-
phodepletion regimen using 500 cGy total body irradiation
(Fig. 1a). A dose escalation was performed to define the dose of
NKTR-214 to administer with ACT in order to achieve an anti-
tumor response with acceptable toxicity profile in mice (Supple-
mentary Fig. 1a–d). NKTR-214 in combination with ACT was
well-tolerated up to 0.8 mg/kg of NKTR-214, which was given
once every 9 days for three doses (q9dx3) as previously shown3.
No difference in tumor delay was observed with a fourth dose
(Supplementary Fig. 1e). The previously reported dosing regimen
for ACT+ IL-2 was used as a comparator (0.4 mg/kg for three
consecutive days, qdx3)15. In order to reasonably balance the
different pharmacokinetic profiles between NKTR-214 and IL-2,
we repeated the qdx3 IL-2 dosing regimen every 9 days to
coincide with the q9dx3 schedule for NKTR-214. The adoptively
transferred cells were only administered on day 1 after lympho-
depletion, and ACT was not repeated with subsequent adminis-
trations of either NKTR-214 or IL-2.
ACT+NKTR-214 led to significant tumor growth inhibition
with less frequent dosing in the aggressive B16-F10 model
compared to ACT+ IL-2 or ACT+ vehicle (Fig. 1b, c). As
demonstrated previously16, pmel-1 ACT without IL-2 supple-
mentation had little to no antitumor benefit in this model,
highlighting the critical role of IL-2 to provide robust antitumor
activity with ACT. Mice receiving ACT+NKTR-214 showed a
median tumor growth delay (evaluated as time to reach a tumor
volume of 1000 mm3) of 42 days compared to ACT+ IL-2 or
ACT+ vehicle (19.5 and 11 days, respectively, Fig. 1c). Two out
of 12 mice in the ACT+NKTR-214 had small tumors neither
growing nor shrinking until the end of the study (Fig. 1c and
Supplementary Fig. 2a). Tumors from these mice showing long
term response were harvested and processed for immunohisto-
chemical (IHC) analysis, which revealed persistent tumor-
infiltrating CD8 T cells in the samples (Supplementary Fig. 2b).
To monitor potential treatment toxicities, we observed mice for
any appearance of clinical signs and measured their body weight
throughout the course of the experiments. Results showed that
mice did not present any weight changes or other observable side
effects after injection of 0.8 mg/kg of NKTR-214 in combination
with ACT (Supplementary Fig. 3a). There was a trend towards
increased CD8 T cells infiltrates in liver and kidney on day 5 after
ACT+NKTR-214 or ACT+ IL-2 as assessed using IHC staining.
These ranged from 0–6% positive cells in kidney and 0–40% in
liver, declining to less than 10% by day 9, prior to administration
of the second dose. These effects did not result in obvious clinical
signs based on the activity level and observed behavior of the
mice (Supplementary Fig. 3b, c).
NKTR-214 expands adoptively transferred CD8 T cells. To
better understand the mechanisms of improved antitumor
activity and T cell trafficking with the ACT+NKTR-214 treat-
ment, pmel-1 Thy1.1+ T cells were genetically modified to
express firefly luciferase, which allows detection of T cells in vivo
using bioluminescence imaging (BLI) to follow the biodistribu-
tion of the adoptively transferred T-cells and tumor-specific
homing (Fig. 2a–c). BLI analysis showed that ACT without IL-2
resulted in minimal to no in vivo expansion of the adoptively
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transferred pmel-1 cells but there was some accumulation in the
tumors due to cognate antigen recognition (Fig. 2a, left column),
as we have previously described17, further portraying the key role
of IL-2 supplementation for an effective antitumor response with
ACT. BLI images from the ACT+NKTR-214 treatment greatly
increased T cell expansion in the spleen from day 5 to day 7
compared to ACT+ IL-2 (Fig. 2a, middle and right columns). At
day 5, quantification of BLI in serial images with region of interest
(ROI) analysis at the site of spleen revealed an average radiance
14-fold higher in ACT+NKTR-214 compared to ACT+ IL-2
treated mice (Fig. 2b). These data were supported by immuno-
PET imaging using cys-diabody (cDb) targeting CD8 in vivo,
allowing whole body non-invasive imaging to study the sites of
accumulation of CD8 T cells (Fig. 2d). In addition, ex vivo bio-
distribution analysis of radioactivity from harvested organs
demonstrated that the signal in the spleen was 5-fold higher in
the ACT+NKTR-214 group compared with the ACT+ IL-2
group on day 5 after treatment (Fig. 2e). CD8 IHC of spleens
analyzed by sequential digital pathology confirmed a significantly
higher expansion of CD8 T cells in mice treated with ACT+
NKTR-214 compared to ACT+ IL-2 (Fig. 2f, g). NKTR-214
triggered a rapid reconstitution of splenic immune cells after
lymphodepletion in the ACT+NKTR-214 treated mice, resulting
in splenocyte cell counts seven times higher than ACT+ IL-2-
treated mice 6 days after total body irradiation (Supplementary
Fig. 4). It was noted that by day 9 and before the second dose of
NKTR-214 or IL-2, a substantial decrease in the BLI signal was
observed in spleen and tumor, independently of the treatment
(Fig. 2b, c and Supplementary Fig. 5a), consistent with a q9d
dosing schedule. The use of anti-CD8 immuno-PET once again
provided confirmation of these kinetics by observation of a
temporary decrease in the CD8 T cell signal in spleen and tumor
by day 9 (Supplementary Fig. 5b, c). Strikingly, the second
NKTR-214 dose administered on day 9 triggered a new expansion
of the adoptively transferred T cells (given only on day 1) in
spleen and tumor, which persisted from day 12 to day 17. In
sharp contrast, minimal secondary expansion was noted in the
group re-dosed with IL-2 (Fig. 2a–c). The peak of T cell infil-
tration in the tumor after the second NKTR-214 dose was
reached at day 14, with an average radiance 6-fold higher in the
ACT+NKTR-214 group compared to the ACT+ IL-2 group
(Fig. 2a–c). No further expansion of CD8 T cells was observed
after the third dose of NKTR-214 performed at day 18 (Fig. 2b, c).
Characterization of cell subsets modulated by ACT+NKTR-
214. To further characterize the functional phenotype of the
treatment-induced immune cell populations, we performed mass
cytometry in spleen and tumors of mice treated with ACT in
combination with NKTR-214 or IL-2 at day 7 and 14, the peak of
the first and second CD8 T cell expansion. Our panel comprised
of T, NK, B, and myeloid cell lineage markers (Supplementary
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Fig. 1 Superior antitumor response by adoptively transferred T cells with NKTR-214 compared to IL-2. a Schematic of the pmel-1 ACT model. Time points in
days throughout the text refer to the number of days post-administration of ACT+NKTR-214 or ACT+ IL-2 at day 0. Subsequent to day 0, no further ACT
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Bonferroni-Dunn multiple comparisons test). (c)Tumor growth delay was assessed for each tumor growth curve by interpolating the time to achieve tumor
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Table 1). We first manually annotated seven main immune
populations from CD45+ cells (Supplementary Fig. 6a) using t-
stochastic neighbor embedding (t-SNE)-generated heat maps
corresponding to myeloid cells, dendritic cells (DC), NK cells, B
cells and T cells (Fig. 3a, b). As expected, the clusters showing
greater differences between treatments were T cell populations,
both in spleen and tumor (Fig. 3a–d). Additionally, in the spleen
the myeloid compartment was increased at day 7 and 14 by ACT
+NKTR-214 treatment (Fig. 3a–c). The robust re-treatment
effect was particularly striking after NKTR-214 compared to IL-2
at day 14 (5 days post-administration of the second dose), con-
firming the in vivo imaging result of Fig. 2c. The NK cluster
expanded preferentially with ACT+ IL-2 at day 7, and with
ACT+NKTR-214 at day 14 (Fig. 3a–c). T-SNE density plots
showed that IL-2 led to preferential B cells expansion in spleen,
on days 7 and 14 (Fig. 3a). Interestingly, dendritic cell popula-
tions represented an important fraction of the tumor immune
cells in both ACT+ IL-2 and ACT+NKTR-214-treated mice at
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an early time point (30.3% and 18.2%, respectively, Fig. 3b–d). In
the tumor at day 7, the two treatments did not differ significantly
in the expansion of any immune population, except for T cells
(Fig. 3b–d). At day 14, IL-2 preferentially expanded NK, while
NKTR-214 expanded dramatically the T cell compartment, sug-
gesting that the T cells are the main contributors in the enhanced
anti-tumor response by NKTR-214 in this model. This finding
was confirmed by IHC-based quantification of CD8-stained
tumor sections, showing a significantly higher number of intra-
tumor lymphocytes in the ACT+NKTR-214 group compared to
ACT+ IL-2 group at day 14 (37.5% vs 9.3% of total tumor cells,
Fig. 4a, b).
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NKTR-214 favors CD8 T cell tumor infiltration over Tregs. We
performed further T cell subset analyses using the mass cytometry
data (Supplementary Fig. 6a). We identified three main sub-
populations: CD8 T cells, CD4 T cells, and Tregs. Confirming
what was described in the previous experiments, analysis of T cell
populations revealed increased expansion and persistence of
adoptively transferred Thy1.1+ CD8 T cells in spleen and tumor
of mice treated with ACT+NKTR-214 compared to ACT+ IL-
2, both at days 7 and 14 days (Fig. 4c, d, Supplementary Fig. 6b,
c). Density plots of the T cell clusters showed the preferential
activation of tumor-specific Thy1.1 +CD8 T cells over Tregs in
spleen and tumor for the ACT+NKTR-214-treated mice, while
the opposite trend was observed in the ACT+ IL-2 group, both at
day 7 and 14 (Fig. 4c–f, Supplementary Fig. 6b, c). While the
Thy1.1/Tregs ratio was two-fold higher in spleen after ACT+
NKTR-214 compared to ACT+ IL-2 at day 7 and 14 (Supple-
mentary Fig. 7a), this ratio was 4 and 11-fold higher in tumor,
respectively (Supplementary Fig. 7b). Remarkably, up to 40% of
intratumor lymphocytes were tumor antigen-specific at day 7 and
up to 22% at day 14 in the ACT+NKTR-214 group (Fig. 4f).
Interestingly, NKTR-214 preferentially expanded Thy1.1+
tumor-specific CD8 T cells over the endogenous Thy1.2+ CD8
T cells in spleen at day 7 after treatment (Fig. 4e, Supplementary
Figs. 6b and 7e). Ki-67 expression marker analysis showed that
ACT+NKTR-214 treatment resulted in an increased prolifera-
tion of T cell clusters, particularly CD8 T cells in spleen and
tumor at both time points (Supplementary Fig. 7c–e). The
expression of PD-1 was low or absent in the spleen of both
treatments (Supplementary Fig. 7c), while NKTR-214 enhanced
activation of T cells in tumor in the mice treated with ACT+
NKTR-214 (Supplementary Fig. 7d).
NKTR-214 treatment increases immune-related gene expres-
sion. To determine the impact of NKTR-214 in combination with
ACT on the tumor microenvironment, we performed RNA
sequencing (RNA-seq) analysis of tumor samples harvested at
day 12. The experiment was conducted two days before the sec-
ond peak of T-cell expansion in tumors of ACT+NKTR-214
treated mice to assess differences at transcriptomic level poten-
tially responsible for the different cellular phenotype between the
two treatments. Hierarchical clustering of the most variable genes
demonstrated that ACT+NKTR-214 induced far greater gene
expression in tumor samples than ACT+ IL-2 treatment
(Fig. 5a). The detailed principal component analysis (PCA)
showing the clustering of the three biological replicates for all
treatment groups is shown in Supplementary Fig 8a. Gene set
enrichment analysis (GSEA) of the genes log2 upregulated
between ACT+NKTR-214 compared to ACT+ IL-2 showed
that the top ten significantly enriched sets from Gene Ontol-
ogy (GO) included immune response, T cell activation and pro-
liferation, and inflammatory-related genes (Fig. 5b). Genes higher
expressed in the ACT+NKTR-214 compared to ACT+ IL-
2 samples include interferon-γ (IFN-γ) (Fig. 5b, Supplementary
Fig. 8b), IL-5, IL-6, IL-15, IL-18, and IL-27 (Supplementary
Fig. 8b), and chemotaxis-related genes (Fig. 5b, Supplementary
Fig. 8c). To better characterize the transcriptional profile of the T
cell population, we focused on the expression of selected genes
with a known role in regulating T cell populations. As expected,
we found an upregulation of key effector genes (perforin, IFN-γ,
and granzymes) in the ACT+NKTR-214 tumors. Increased
expression of these genes and Pdcd1 (PD-1), Cd28 and Klrg1
showed the presence of highly cytotoxic effector CD8 T cells in
the ACT+NKTR-214 tumors. Over-expression of the inhibitory
receptors Ctla4, Lag3, Havcr2 (Tim-3) and Tigit, as well as the
transcription factors Tbx21 (T-bet) and Eomes, suggests the
increased presence of T cells that had previously signaled through
their TCR after NKTR-214 treatment. Interestingly, genes highly
expressed in ACT+NKTR-214 tumors also included markers of
memory T cells such as Il7r (CD127), Cd44 and Sell (CD62L),
reflecting the heterogeneity of T cell populations induced by
NKTR-214 treatment.
NKTR-214 increases tumor-specific T cell polyfunctionality. To
compare the functional properties of T cells between ACT+
NKTR-214 and ACT+ IL-2 treated-mice, we evaluated the ability
of the adoptively transferred Thy1.1+ CD8 T cells to secrete
multiple (>2) cytokines per cell, termed polyfunctionality. We
utilized a multiplexed antibody coated chip that allows analyzing
thousands of T-cells at the single-cell level for the frequency and
intensity of secretion of 28 cytokines (IsoCode Chip, Fig. 5d).
Thy1.1+ cells from mice treated in vivo with ACT+NKTR-
214 showed an enhanced ability to induce polyfunctional T-cells.
In both spleen and tumor, ACT+NKTR-214 increased poly-
functionality by 1.7 and 10 fold, respectively, compared to ACT
+ IL-2 (Fig. 5e). Though the percentage of cells secreting two
cytokines was almost identical in the spleen (2.2% vs. 2.4%,
respectively), exposure to NKTR-214 induced a subset of cells to
become highly polyfunctional. Zero percent of the adoptively
transferred T cells were highly polyfunctional in the spleen
samples from mice exposed to ACT+ IL-2. In contrast, ACT+
NKTR-214 elicited a 21-fold increase in the polyfunctional
strength index (PSI, defined as the percentage of polyfunctional
cells in the sample, multiplied by the intensities of the secreted
cytokines) of Thy 1.1+ CD8 T cells (Fig. 5e). Moreover, ACT+
NKTR-214 treatment elicited a 1200-fold increase in PSI of the
TILs compared to ACT+ IL-2. The increased polyfunctional
response by NKTR-214 was driven by the production of the
chemoattractive RANTES, followed by MIP-1α, granzyme B, and
IFN-γ effector cytokines (Supplementary Fig. 9a). In particular,
NKTR-214 increased the secretion frequency and intensity of
IFN-γ and MIP-1α in splenic T cells while enhancing granzyme
B, MIP-1α, RANTES and decreasing the regulatory/immune
suppressive TGF-β in T cells obtained from tumors (Supple-
mentary Fig. 9b, c). The single-cell polyfunctional heatmap
shown in Fig. 5f demonstrated the increase in polyfunctional T
cell subsets that co-produce combination cytokines in spleen and
tumor after NKTR-214.
Fig. 4 Increased T cell infiltration is a significant component of NKTR-214′s anti-tumor efficacy. a Immunohistochemistry (IHC) CD8 T cells staining in
tumors at different time points, representative image of three replicates per group. HALO software analysis showing intensity of marker expression, from
low expression (blue) to high expression (red). b HALO software digital quantification of IHC slides showing the percentage of CD8 T cells infiltrating the
tumor at different time points. *p < 0.05, ****p < 0.0001, mean ± s.e.m, unpaired t-test. c, d Mass cytometry results on T cells compartment. T-SNE plots
showing annotated clusters (upper panels), density plots (middle panels) and Thy1.1 marker expression level plot (lower panels) in spleen (c) and tumor at
day 14 (d). Density scale bar represents marker expression of cells for a given cluster, ranging from low expression (blue) to high expression (red). In the T
cell subsets panels, yellow dots represent CD4+ T cells (TCD4), blue dot: CD8+ T cells (TCD8), orange dots regulatory T cells (Treg), light grey dots:
unidentified cluster (uic). e, f Cell frequencies at day 7 and 14 after treatment were calculated for the annotated T cell clusters and displayed on a per-
mouse basis in spleen (e) and tumor (f). Mean ± s.e.m (n= 3), *p < 0.05, ****p < 0.0001, unpaired t-test. The experiment is representative of two
replicates.
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Enhanced polyfunctionality of patient’s blood immune cells
with NKTR-214 monotherapy. To explore if the administration
of NKTR-214 to humans also induced increased polyfunctional
profile of CD4, CD8, and NK cells, as we noted in the mouse
model, we used the same single cell polyfunctionality assay chip
to analyzed peripheral blood mononuclear cells from five patients
treated with NKTR-214 within a phase I dose escalation study
(NCT02869295). Results showed that NKTR-214 induced distinct
polyfunctional responses in the cell subsets at days eight of cycle
one (C1D8), eight of cycle two (C2D1 and C2D8) and one of
cycle three (C3D1), compared to pre-dose (cycle one day one,
C1D1). NKTR-214 upregulated the PSI of NK cells in blood
samples from all the patients after one course of treatment, with a
higher increase after the second dose of NKTR-214 (Fig. 6). The
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PSI of CD4 and CD8 T cells was not affected by the treatment in
patient one, while the single-cell polyfunctional strength of CD4
and CD8 T cells in the other four patients was enhanced after
NKTR-214 administration, with PSI peaking at various time
points in different patients (Fig. 6) demonstrating the importance
of serial sampling. Effector and stimulatory cytokines dominated
the profiles of all the cell subsets (Fig. 6). Specifically, for CD4 and
CD8 T cells the major drivers for increased PSI were TNF-α, IFN-
γ, and IL-5 (Supplementary Fig. 10a, b).
Discussion
In this study, we describe the superior anti-tumor efficacy of
NKTR-214 compared to IL-2 to support the antitumor activity of
adoptively transferred T cells in a preclinical model. We show
that the combined therapy including NKTR-214 was able to
control the growth of large, poorly immunogenic tumors and was
associated with substantially higher expansion, tumor targeting
and persistence of polyfunctional anti-tumor CD8 effector T cells.
Increased number of polyfunctional CD8 T cells was also
observed in peripheral blood of patients treated with NKTR-214
as a single agent within a phase 1 clinical trial18.
Different attempts have been made to use the beneficial effects
of the IL-2 pathway while limiting its toxicities to improve
therapeutic potential. These approaches include mutated versions
of IL-2 with higher binding affinity towards the IL2Rβ11, Fc
fusion proteins to increase IL-2 serum half-life19 and IL-2/anti-
IL-2 antibody complexes preferentially activating CD8 effector
T cells20,21. A recent study set out to improve the efficacy of ACT
and mitigate toxicities using engineered orthogonal IL-2 cyto-
kine-orthogonal IL-2-receptor pairs able to bind exclusively with
each other, but not with the endogenous counterpart12. All these
modifications showed promising results in animal models; how-
ever, they need to be evaluated in the clinic to assess potential
in vivo effects in humans. NKTR-214 is in active clinical testing
and its improved pharmacokinetics and pharmacodynamics over
IL-2 mitigating immediate over-activation of the immune system
and facilitate tolerability3. The sequential release of PEG chains
avoids the rapid systemic immune activation upon administration
while providing sustained signaling preferentially through the
IL2Rβγ pathway. The pegylation has the additional ability to
decrease the affinity for IL2Rαβγ, constitutive to Tregs, to a
greater extent than the affinity for IL2Rβγ, thus favoring the
expansion of effector T cells compared to Tregs in the tumor as
Fig. 5 NKTR-214 elicits a marked upregulation of immune gene expression and T cell polyfunctionality. a Heatmap representing hierarchical clustering of
the most variable genes (~1500 genes) in the ACT+NKTR-214 and ACT+ IL-2 treated group (n= 3/group). b Gene set enrichment analysis of log2 fold-
change of ACT+NKTR-214 and ACT+ IL-2 samples, representing the top-10 biological pathways with significant gene induction. NES: normalized
enrichment score; FDR: false discovery rate. c Bar charts of select T cell genes. Mean ± s.e.m (n= 3), **p < 0.01, ***p < 0.001, ****p < 0.0001, ns= not
significant, unpaired t-test. d–f Single cell measure of polyfunctionality and polyfunctional strength of adoptively transferred T cells from spleen and tumors
(pool of 3 each/group). d Schematic of the single cell IsoCode chip to analyze T cell polyfunctionality. e Single-cell polyfunctionality (left) and
polyfunctional strength index (PSI) (right) graphs. Polyfuctionality: co-secretion of 2+ cytokines per cell; PSI: percentage of polyfunctional cells in the
sample, multiplied by the intensities of the secreted cytokines. S: spleen. T: tumor. f Single-cell polyfunctional heat map illustrates the single-cell cytokine
combinations being secreted by each sample. Each column corresponds to a specific cytokine or combination of cytokines, and the orange squares
represent the frequency at which the group was secreted by the corresponding sample. The cytokine groups are ordered by overall frequency across all the
samples.
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previously described3,13. These combined attributes result in a
convenient dosing schedule (every 3 weeks) in human clinical
trials. Currently, NKTR-214 is being evaluated clinically in an
out-patient setting (NCT02869295) and has shown favorable
safety profile8.
Interestingly in our studies, the CD8/Tregs ratio was sub-
stantially increased in the tumor of mice treated with ACT+
NKTR-214, while the ratio was much lower in the spleen, prob-
ably due to the homing and preferential expansion of specific
pmel-1 effector T cells into the tumor as demonstrated here using
several imaging and enumeration methodologies22. Local secre-
tion of specific chemokines is thought to favor the migration of
T cells into the tumor microenvironment23. In our study, tran-
scriptomic profiles showed upregulation of several chemokines
and their receptors in tumors of mice treated with ACT+NKTR-
214, including CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7,
CCL8, and CXCR3, previously reported to be associated with
presence of effector T cells in the tumor site24. The adoptively
transferred T cells recruited into the tumors of mice treated with
NKTR-214 were highly polyfunctional, and capable to simulta-
neously producing chemoattractive and effector cytokines and to
sustain a longer anti-tumor response, as previously reported in
clinical trials25,26. In addition to enhanced polyfunctionality,
these cells delivered high concentrations of cytokines per cell. The
ability of the infiltrated T cells to secrete IFN-γ, granzymes, and
perforin both in preclinical and clinical setting18 supports the
ability of NKTR-214 to strongly activate a pool of cytotoxic
effector T cells. Interestingly, RNA sequencing data in our mouse
model shows the coexistence of T cell effector and exhaustion (or
dysfunction) genes with genes related to memory function. This
characteristic has been previously described and can be a
mechanism to achieve both rapid tumor-cells killing and long-
lasting anti-tumor response27.
Adoptive T cell transfer therapy with TIL or TCR engineered
T cells requires supplemental IL-2 to provide the adequate IL-2-
gamma receptor signaling support for brisk T cell proliferation in
the host, which is not required with T cells expressing a chimeric
antigen receptor (CAR) supposedly due to the provision of costi-
mulatory signaling by the CAR. Together, our results suggest that
NKTR-214 supports the expansion and functionality of adoptively
transferred T cells. These characteristics, together with low levels of
immune suppressive Tregs at the tumor site, are thought to be
fundamental for the proper efficacy of immunotherapies28. The
robust and long-lasting effect of NKTR214 in our preclinical ACT
model support its additional potential use in combination with T
cell-based adoptively transferred therapeutics.
Methods
Mice, cell lines and reagents. C57BL/6 mice (Thy1.2+, The Jackson Laboratory,
Bar Harbor, ME) and pmel-1 (Thy1.1+) transgenic mice were generously provided
by Dr. Robert Prins, Department of Neurosurgery at the University of California,
Los Angeles (UCLA). All mouse model experiments were performed in defined-
flora pathogen-free conditions at the AALAC-approved animal facility of the
Division of Experimental Radiation Oncology, UCLA following protocol # 2004-
159-43I after review and approval by the UCLA Animal Research Committee. B16-
F10 is a gp100 positive spontaneous murine melanoma obtained from the
American Type Culture Collection (ATCC, Manassas, VA). All the cell lines are
mycoplasma-free and were regularly tested for mycoplasma contamination. B16-
F10 were authenticated by CellCheck Mouse Test (IDEXX, Westbrook, ME). Cells
were cultured with RPMI containing 2 mM L-glutamine (Corning, Corning, NY)
with 10% fetal calf serum (Omega Scientific, Tarzana, CA). NKTR-214 was
obtained under a material transfer agreement (MTA) with Nektar Therapeutics
(San Francisco, CA). Human recombinant IL-2 (aldesleukin) was purchased from
Prometheus Therapeutics & Diagnostic (San Diego, CA).
Pmel-1 ACT in vivo model. C57/BL6 mice were implanted subcutaneously with
B16-F10 syngeneic murine melanoma cell line on day-7 and lymphodepleted with
500 cGy of total body irradiation on day-1. Splenocytes from pmel-1 donor mice
were depleted of erythrocytes by hypotonic lysis, cultured in RPMI (Corning)
culture media with 50 IU/ml mIL-2 (PeproTech, Rocky Hill, NJ) in the presence of
1 μg/ml gp10025–33 peptide (AnaSpec, Fremont, CA), and used on days 3–5 after
start of the culture. On day 0, when the tumors reached the volume of at least 150
mm3, mice received 2 × 106 peptide-activated pmel-1 splenocytes intravenously
(i.v.) plus NKTR-214 (0.8 mg/kg, q9dx3, i.v.), IL-2 (0.4 mg/kg, qdX3 every 9 days
for 3 cycles, via intraperitoneal injection, i.p.) or vehicle. Tumors were followed by
caliper measurements three times per week.
Immunohistochemistry. Immunohistochemical staining was performed on
paraffin-embedded spleen, tumor, kidney and liver samples at the UCLA Anatomic
Pathology IHC Laboratory. Sections were cut at 4μm thickness and paraffin
removed with xylene and rehydrated through graded ethanol. Endogenous per-
oxidase activity was blocked with 3% hydrogen peroxide in methanol for 10 min.
Heat-induced antigen retrieval (HIER) was carried out for all sections with 0.001M
EDTA buffer, pH= 8.00 using a Biocare decloaker at 95 °C for 25 min. The slides
were then incubated for 1 h at room temperature with CD8a (Invitrogen, Carlsbad,
CA) at 1/100 dilution, followed by a 30 min incubation with rabbit anti rat sec-
ondary. The signal was detected using an anti Rabbit HRP conjugated Polymer
(Agilent, Santa Clara, CA) and visualized with the diaminobenzidine reaction. The
slides were counterstained with hematoxylin, dehydrated and covered. The imaging
and quantification was performed with the HALO Next Generation imaging
analysis software (Indica Labs, Corrales, NM). The percentage of CD8 T cells in the
slide was automatically counted with the HALO software.
Bioluminescence imaging. Three days after pmel-1 splenocytes harvest and cul-
ture, cells were transduced to express firefly luciferase, using a retroviral vector
pMSCV containing a 5′LTR-driven thermostable variant of firefly luciferase,
generously provided by Dr. Robert Prins, Department of Neurosurgery at the
University of California, Los Angeles (UCLA)29. 48 h after transduction, cells were
collected, washed and used for ACT. In vivo bioluminescence imaging was per-
formed on tumor-bearing mice for firefly luciferase transduced-Pmel-1 T cell
trafficking. Prior to imaging, mice were anesthetized with 2% Isoflurane, injected
intraperitoneally with 100 µl of 30 mg/ml of the luciferase substrate, D-Luciferin
(Xenogen Corp., Alameda, CA) in PBS. Mice were shaved to minimize the amount
of light absorbed by black fur. The Xenogen IVIS 200 Imaging System (Xenogen/
Caliper Life Sciences, Waltham, MA) was used to detect photon emission from
tumor-bearing mice with an acquisition time of 0.5–1 min17. Analyses of the
images were performed using Living Image software (Xenogen) and Igor Image
analysis software (Wave Metrics, Lake Oswego, OR) by drawing regions of interest
over the region and obtaining maximum values in photons/second/cm2/steradian.
Immuno-PET imaging and ex vivo biodistribution. Non-invasive immuno-PET
tracking CD8 T cells in vivo was performed using 89Zr-desferrioxamine-labeled
anti-CD8 cys-diabody (cDb) at the UCLA Preclinical Imaging Technology Center,
Crump Institute30. For microPET imaging, 150 µL doses containing Zr-89 radi-
olabeled cDb were prepared in saline for i.v. injection. Mice were anesthetized
using 2% isoflurane and microPET scans were acquired using an Inveon microPET
scanner (Siemens, Munich, Germany) followed by microCT scan (ImTek,
Wedesboro, NJ). MicroPET images were reconstructed using non-attenuation or
scatter corrected maximum a posteriori (MAP) reconstruction and AMIDE was
used for image analysis and display31. At 24 h post-injection, mice were euthanized,
the organs and blood were collected, weighed and the radioactivity was counted to
assess CD8 T cells biodistribution. The percent-injected dose per gram of tissue (%
ID/g) was calculated using a standard containing one percent of the injected dose31.
Mass cytometry. Tumors harvested from mice treated with ACT+ IL-2 or ACT+
NKTR-214 were digested using the Tumor Dissociation Kit, mouse (Miltenyi, Ber-
gisch Gladbach, Germany). Spleen were dissociated through a 70 μm cell strainer and
red blood cells lysed using the ACK lysis buffer (Lonza, Basel, Switzerland). Sple-
nocytes and tumor cells staining and data acquisition were performed using a pro-
tocol adapted from Wei and colleagues32. Metal-conjugated antibodies were
purchased from Fluidigm (San Francisco, CA), Biolegend and Thermo Fisher or
conjugated to unlabeled antibodies at the UCLA Flow Cytometry Core. The mass
cytometry staining panel is described in Supplementary Table 1. Cells were washed in
PBS and resuspended at a concentration of 1–5 × 106 cells/mL in serum-free
RPMI (Corning) and live–dead stained with 5 μmol/L cisplatin (Fluidigm) for 5min
at 37 °C. Cells were washed and stained with a surface protein antibody cocktail for
30min at room temperature, and were then washed and spun for 10min at 4 °C. Cells
were then fixed using a FoxP3/transcription factor–specific fixation buffer
(eBioscience, Santa Clara, California) for 1 h at room temperature, followed by
addition of the FoxP3/transcription factor permeabilization buffer, and were spun for
10min at 4 °C. Cells were then stained with an intracellular antibody cocktail for 1 h
at room temperature. Finally, cells were incubated for 1 h at room temperature with
250 nmol/L iridium intercalator (Fluidigm) to label cellular DNA. Cells were then
washed with PBS, and finally with distilled water. Samples were interrogated using
a Helios mass cytometer (Fluidigm, San Francisco, CA) at the UCLA Flow
Cytometry Core Facility. Samples were manually gated in FlowJo by stability of time,
cells with no beads (Ir193+/Ce140−), cleanup (double positive for DNA), singlets
(Ir193+), live (195Pt−/CD45+) and by the desired expression markers (CD45+ or
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(CD45+Cd11b- Cd11c- CD19- CD161- to gate the T cells) for each particular
analysis (Supplementary Fig. 6a). Mass cytometry data analysis was performed using
the open-source R/Bioconductor package cytofkit33. Individual sample data were
subsampled to 5,000 events. We set this cut-off based on the reasoning that 5000
events would be sufficient for phenotypic clustering and dimension reduction ana-
lyses. PhenoGraph clustering and t-Distributed Stochastic Neighbor Embedding
(t-SNE) plots were performed using cytofkit for cell subsets detection, visualization,
and interpretation. For t-SNE plots overlaid with expression of individual parameters,
signal intensity is displayed in arcsinh transformed values.
RNA extraction, sequencing, and analysis. Total RNA extraction was performed
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) from B16-F10 tumors
treated with ACT+ IL-2 and ACT+NKTR-214. RNA sequencing was performed
using the Illumina HiSeq 3000 platform on 50-bp single-end libraries at the UCLA
technology Center for Genomics & Bioinformatics. Reads were mapped using
HISAT2 version 2.0.434 and aligned to the Mus musculus genome NCBI build
GRCm38. Reads were quantified HTSeq version 0.6.135 and normalized to frag-
ments per kilobase of exon per million fragments mapped (FPKM) expression
values. FPKM values were then log2 transformed with an offset of 1. Hierarchical
clustering was performed on z-scored gene expression values with complete linkage
using the Euclidean distance metric using R (http://www.R-project.org/). To
identify pathways enriched in the ACT+NKTR-214-treated tumors, Gene Set
Enrichment Analysis (GSEA) was performed using the pre-ranked option. Genes
were ranked by log2 fold changes between ACT+ IL-2 and ACT+NKTR-214.
Enrichment was assessed across the curated Molecular Signatures Database C5 GO
biological process gene sets36.
Single-cell multiplex cytokine profiling of murine T cells. CD8 pmel-1 (Thy-1.1
+) T cells from spleen and tumors of mice treated with ACT+ IL-2 or ACT+
NKTR-214 (3 mice/group) were collected at day 7 after treatment, pooled and
sorted using Alexa Fluor 700 anti-mouse CD90.1 (Thy1.1), clone OX-7 antibody
(Biolegend, San Diego, CA). Sorted cells were stimulated with immobilized anti-
mouse CD3 (Invitrogen) and soluble anti-mouse CD28 (Invitrogen) at 37 °C, 5%
CO2 for 48 h. After stimulation, cells were stained with Alexa Fluor 647-conjugated
anti-mouse CD8 (Biolegend) at room temperature for 20 min. Approximately
30,000 T cells were loaded onto an IsoCode chip (IsoPlexis, New Heaven, CN)
containing ~12,000 microchambers pre-patterned with a 28-plex antibody array,
imaged for single cell location in microchambers and incubated at 37 °C, 5% CO2
for additional 16 h. Following incubation period, ELISA detection was used to
determine which combinations of proteins were being secreted by each individual
cell. Secreted proteins from single cells were captured by antibody-barcoded slides;
the polyfunctional profile (2+ proteins per cell) of single cells was evaluated by
IsoPlexis’ software.
Patient samples. Fifteen cryopreserved peripheral blood mononuclear cells
(PBMC) from patients with histologically confirmed locally advanced or metastatic
solid tumors were provided by the Department of Melanoma Medical Oncology,
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center,
Houston, TX. This study is a phase I dose escalation study, identified as
NCT02869295 on www.clinicaltrial.gov. We are not reporting the results of the
clinical trial, in this article, we report the analyses on blood cell samples obtained
from a subset of five subjects. Patients were treated with 0.003 or 0.006 mg per kg
body weight (mg/kg) every 2 weeks or every 3 weeks as a 15 –min i.v. infusion.
Blood to obtain PBMC was collected on the first day of treatment (C1D1), at week
1 after treatment (C1D8), at day one and eight of cycle two (C2D1 and C2D8) and
at day one of cycle three (C3D1). The study was approved by the institutional
review board of University of Texas MD Anderson Cancer Center. Informed
consent was obtained from all participants.
Single-cell multiplex cytokine profiling of human PBMC. PBMCs from five
patients were thawed and recovered in the complete RPMI media (Thermo Fisher
Scientific, Waltham, MA) with 10 ng/ml IL-2 (Biolegend) at 37 °C, 5% CO2. After
overnight incubation, viable cells were enriched by Ficoll. CD4+ T cells, CD8
T cells and NK cells were separated by anti-CD4, anti-CD8 or anti-CD56
microbeads (Miltenyi). Enriched NK cells were labeled with Carboxyfluorescein
succinimidyl ester (CFSE, Thermo Fisher Scientific), rinsed and resuspended in
RPMI media at a density of 1 × 106/ml with addition of PMA (5 ng/ml, Sigma-
Aldrich) and Ionomycin (500 ng/ml, Sigma-Aldrich) to be loaded onto an IsoCode
chip (IsoPlexis). Enriched CD4 and CD8 T cells were resuspended in fresh com-
plete RPMI media at 1 × 106/ml and activated with immobilized anti-human CD3
(10 ug/ml, Thermo Fisher Scientific) and soluble anti-human CD28 (5 ug/ml,
Thermo Fisher Scientific) in a 96-well flat-bottom plate (Corning Life Science) at
37 °C, 5% CO2 for 24 h. After stimulation, cells were stained with PE-conjugated
anti-human CD4 (Biolegend) or Alexa Fluor 647-conjugated anti-human CD8
(Biolegend) at room temperature for 20 min and loaded onto an IsoCode chip.
Each IsoCode chip contains ~12,000 microchambers pre-patterned with a full copy
of 32-plex antibody array including Effector: Granzyme B, TNFα, IFN-γ, MIP1α,
Perforin, TNFβ; Stimulatory: GM-CSF, IL-2, IL-5, IL-7, IL-8, IL-9, IL-12, IL-15, IL-
21; Chemoattractive: CCL11, IP-10, MIP-1β, RANTES; Regulatory: IL-4, IL-10,
IL-13, IL-22, sCD137, sCD40L, TGFβ1; Inflammatory: IL-6, IL-17A, IL-17F, MCP-
1, MCP-4, IL-1β. The polyfunctional profile (2+ proteins per cell) of single cells
was evaluated by IsoSpeak software.
Statistical analyses. Data are presented as mean ± SEM and representative of at
least two independent experiments. In tumor growth studies the significance
between experimental groups (ACT+ vehicle, ACT+ IL-2 and ACT+NKTR-
214) was defined using ANOVA, with the Bonferroni-Dunn multiple comparison
post-test. Differences in Kaplan–Meier survival curves showing tumor delay (time
to achieve tumor volume of 1000 mm3) were calculated using Mantel–Cox test. P-
values were calculated using two-way ANOVA (Tukey’s multiple comparison) to
compare the intensity of ROI in BLI experiments. Differences between NKTR-214
and IL-2 were analyzed using unpaired Student’s t-test. P-values < 0.05 were con-
sidered significant. Statistical analyses were performed using GraphPad Prism
version 7.03 (GraphPad Software).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors state that all data generated during this study are within the article and its
supplementary information files and from the corresponding author upon reasonable
request. The RNA sequencing data have been deposited in the GEO database under the
accession code GSE118748. A reporting summary for this article is available as a
Supplementary Information file.
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